Table 1.

Baseline characteristics of participants according to groups.

	Non-AD			MCI			CN
	MBI > 0	MBI = 0	p value	MBI > 0	MBI = 0	p value	MBI > 0	MBI = 0	p value
No.	n = 385	n = 744		n = 296	n = 247		n = 89	n = 497
Age	71.68 ± 7.25	72.35 ± 6.25	0.032	71.67 ± 7.57	72.48 ± 7.18	0.026	71.71 ± 6.07	72.23 ± 6.25	0.215
Education (year)	16 (14–18)	16 (15–18)	0.456	16 (14–18)	16 (14–18)	0.444	16 (15–18)	17 (15–18)	0.654
Female	162 (42.07%)	401 (53.89%)	0.321	110 (37.16%)	121 (48.98%)	0.219	52 (58.42%)	279 (56.13%)	0.341
APOE ɛ4 carriers	170 (44.15%)	267 (35.88%)	0.004	145 (48.98%)	111 (44.93%)	0.013	25 (28.08%)	156 (31.38%)	0.134
Florbetapir	n = 349 1.206 ± 0.231	n = 591 1.147 ± 0.198	0.002	n = 275 1.238 ± 0.236	n = 217 1.201 ± 0.222	0.044	n = 74 1.087 ± 0.168	n = 374 1.116 ± 0.176	0.606
Flortaucipir	n = 162 1.198 ± 0.158	n = 378 1.188 ± 0.168	0.125	n = 87 1.236 ± 0.205	n = 79 1.260 ± 0.246	0.146	n = 75 1.150 ± 0.096	n = 299 1.163 ± 0.136	0.067
FDG	n = 353 1.256 ± 0.131	n = 524 1.291 ± 0.123	0.769	n = 281 1.243 ± 0.129	n = 240 1.270 ± 0.135	0.654	n = 72 1.308 ± 0.128	n = 284 1.310 ± 0.108	0.089
ADAS	n = 339 9.18 ± 5.17	n = 588 7.40 ± 3.72	<0.001	n = 265 9.95 ± 5.27	n = 216 9.18 ± 4.06	0.222	n = 74 6.31 ± 3.56	n = 372 6.37 ± 3.07	0.688
MMSE	n = 339 28.05 ± 2.05	n = 591 28.68 ± 1.47	<0.001	n = 265 27.80 ± 2.15	n = 217 28.08 ± 1.68	0.044	n = 74 28.97 ± 1.28	n = 374 29.02 ± 1.21	0.280

No. number of participants, MBI mild behavioral impairment, APOE ɛ4 apolipoprotein E gene, Non-AD participants without alzheimer’s disease, MCI mild cognition impairment, CN cognitively normal, FDG 18F-fluorodeoxyglucose, ADAS Alzheimer’s disease assessment scale, MMSE mini-mental state examination, MoCA Montreal cognitive scale.